Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aminohippurate Sodium

FDA-approved product (injectable, injection), marketed as Aminohippurate Sodium.

Registered studies
29
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Aminohippurate Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Aminohippurate Sodium. Its therapeutic class is shown instead.

WHO therapeutic group
Tests for renal function and ureteral injuries
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Aminohippurate Sodium, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA12.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

29registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aminohippurate Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aminohippurate Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Transgender Analysis of Nephrological Studies Focused on Renal Metrics

    NCT07542964 · start 2026-09

    Registered record
    Registry ID
    NCT07542964
    Conditions
    Kidney Disease; Kidney Injury; Transgender Individuals
    Interventions
    P-aminohippurate clearance study; Iohexol infusion; Hyperinsulinemic clamp
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2028-09
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Disease; Kidney Injury; Transgender Individuals
    InterventionP-aminohippurate clearance study; Iohexol infusion; Hyperinsulinemic clamp
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Effect of Acute Hypoxia on Renal Hemodynamic in Healthy Volunteers, Patients With Diabetes and Patients With Diabetes and Kidney Disease

    NCT06846034 · start 2025-02-13

    Registered record
    Registry ID
    NCT06846034
    Conditions
    Diabetes; Diabetic Kidney Disease; Hypoxia; Healthy Volunteer; Diabetic Nephropathies
    Interventions
    Hypoxia administration study group; Renal clairance study
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-02-13
    Completion
    2026-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetic Kidney Disease; Hypoxia; Healthy Volunteer +1 more
    InterventionHypoxia administration study group; Renal clairance study
    PhaseNot applicable
    Registry statusRecruiting

  • Investigations Into Sepsis-associated Acute Kidney Injury

    NCT05694624 · start 2023-08-14

    Registered record
    Registry ID
    NCT05694624
    Conditions
    Acute Kidney Injury
    Interventions
    Para Aminohippurate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-08-14
    Completion
    2026-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury
    InterventionPara Aminohippurate
    PhaseNot recorded
    Registry statusRecruiting

  • Renal Mechanism of SGLT2 Inhibition

    NCT05507892 · start 2022-10-10

    Registered record
    Registry ID
    NCT05507892
    Conditions
    Type 2 Diabetes; Diabetic Kidney Disease
    Interventions
    canagliflozin; Aminohippurate Sodium Inj 20%
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-10-10
    Completion
    2026-12-15
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Diabetic Kidney Disease
    Interventioncanagliflozin; Aminohippurate Sodium Inj 20%
    PhasePhase 2
    Registry statusActive not recruiting

  • Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study

    NCT05530356 · start 2022-09-30

    Registered record
    Registry ID
    NCT05530356
    Conditions
    Type 2 Diabetes; Diabetes Type 2; Diabetic Nephropathies; Nephropathy; Obesity; Adolescent Obesity; Diabetic Kidney Disease
    Interventions
    Aminohippurate Sodium Inj 20%; Iohexol Inj 300 MG/ML; Dextran 40; Renal Biopsy; Positron Emission Tomography
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-09-30
    Completion
    2024-06-19
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Diabetes Type 2; Diabetic Nephropathies; Nephropathy +3 more
    InterventionAminohippurate Sodium Inj 20%; Iohexol Inj 300 MG/ML; Dextran 40; Renal Biopsy +1 more
    PhaseNot recorded
    Registry statusCompleted

  • MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

    NCT05065372 · start 2022-07-01

    Registered record
    Registry ID
    NCT05065372
    Conditions
    Type 1 Diabetes; Diabetic Kidney Disease; Cardiovascular Diseases; Endothelial Dysfunction; Insulin Sensitivity
    Interventions
    Metformin Hcl 1000Mg Tab; Aminohippurate Sodium 20 % Injection; Iohexol 300 Mg/mL Injectable Solution; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-07-01
    Completion
    2027-07-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes; Diabetic Kidney Disease; Cardiovascular Diseases; Endothelial Dysfunction +1 more
    InterventionMetformin Hcl 1000Mg Tab; Aminohippurate Sodium 20 % Injection; Iohexol 300 Mg/mL Injectable Solution; Placebo
    PhasePhase 1
    Registry statusRecruiting

  • Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

    NCT05319990 · start 2022-03-09

    Registered record
    Registry ID
    NCT05319990
    Conditions
    Type 1 Diabetes; Diabetic Kidney Disease; Diabetes Complications; Diabetic Nephropathies; Autoimmune Diabetes
    Interventions
    Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF); Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2022-03-09
    Completion
    2027-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes; Diabetic Kidney Disease; Diabetes Complications; Diabetic Nephropathies +1 more
    InterventionAminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF); Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
    PhaseNot recorded
    Registry statusActive not recruiting

  • Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

    NCT05008276 · start 2021-09-27

    Registered record
    Registry ID
    NCT05008276
    Conditions
    Type 2 Diabetes Mellitus; Diabetic Kidney Disease; Adolescent Obesity; Pre Diabetes; Kidney Hypoxia; Puberty
    Interventions
    Aminohippurate Sodium Inj 20%; Iohexol Inj 300 MG/ML; Dextran 40
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-09-27
    Completion
    2027-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Diabetic Kidney Disease; Adolescent Obesity; Pre Diabetes +2 more
    InterventionAminohippurate Sodium Inj 20%; Iohexol Inj 300 MG/ML; Dextran 40
    PhaseNot recorded
    Registry statusRecruiting

  • Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

    NCT04649229 · start 2021-05-27

    Registered record
    Registry ID
    NCT04649229
    Conditions
    Heart Failure
    Interventions
    LCZ 696; Placebo; Para-aminohippurate; Iohexol; Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-05-27
    Completion
    2025-05-22
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionLCZ 696; Placebo; Para-aminohippurate; Iohexol +1 more
    PhasePhase 4
    Registry statusCompleted

  • Effect of Hormone Therapy on Renal Function

    NCT04482920 · start 2021-04-15

    Registered record
    Registry ID
    NCT04482920
    Conditions
    Transgenderism; Kidney Diseases; Kidney Injury
    Interventions
    p-aminohippurate clearance study; Iohexol infusion
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-04-15
    Completion
    2023-08-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransgenderism; Kidney Diseases; Kidney Injury
    Interventionp-aminohippurate clearance study; Iohexol infusion
    PhaseNot recorded
    Registry statusCompleted

  • PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

    NCT04407481 · start 2020-11-01

    Registered record
    Registry ID
    NCT04407481
    Conditions
    Polycystic Kidney Disease, Adult; Polycystic Kidney, Autosomal Dominant
    Interventions
    Aminohippurate Sodium Inj 20%; Iohexol Inj 300 milligrams per milliliter (MG/ML); PET/CT Scan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-01
    Completion
    2022-10-13
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Kidney Disease, Adult; Polycystic Kidney, Autosomal Dominant
    InterventionAminohippurate Sodium Inj 20%; Iohexol Inj 300 milligrams per milliliter (MG/ML); PET/CT Scan
    PhaseNot recorded
    Registry statusCompleted

  • Apelin as a Potential Treatment for Chronic Kidney Disease

    NCT03956576 · start 2020-02-04

    Registered record
    Registry ID
    NCT03956576
    Conditions
    Chronic Kidney Diseases; Cardiovascular Diseases; Endothelial Dysfunction
    Interventions
    [Pyr]apelin-13
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-02-04
    Completion
    2022-12-14
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Diseases; Cardiovascular Diseases; Endothelial Dysfunction
    Intervention[Pyr]apelin-13
    PhaseNot applicable
    Registry statusCompleted

  • Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance

    NCT04074668 · start 2020-01-01

    Registered record
    Registry ID
    NCT04074668
    Conditions
    Diabetic Kidney Disease; Type 1 Diabetes; Diabetes; Diabetes Mellitus; Diabetes Complications; Diabetic Nephropathies; Type1diabetes; Diabetes, Autoimmune; Autoimmune Diabetes; Juvenile Diabetes; Type 1 Diabetes Mellitus
    Interventions
    Aminohippurate Sodium Inj 20%; Iohexol Inj 300 milligrams/milliliter (mg/ml); PET/CT Scan; Renal Biopsy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2022-11-15
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease; Type 1 Diabetes; Diabetes; Diabetes Mellitus +7 more
    InterventionAminohippurate Sodium Inj 20%; Iohexol Inj 300 milligrams/milliliter (mg/ml); PET/CT Scan; Renal Biopsy
    PhaseNot recorded
    Registry statusCompleted

  • Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

    NCT04113109 · start 2019-11-01

    Registered record
    Registry ID
    NCT04113109
    Conditions
    Heart Failure
    Interventions
    LCZ 696; Icatibant; placebo; Para-aminohippurate; Iohexol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-11-01
    Completion
    2025-07-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionLCZ 696; Icatibant; placebo; Para-aminohippurate +1 more
    PhasePhase 4
    Registry statusCompleted

  • An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

    NCT04008992 · start 2019-06-18

    Registered record
    Registry ID
    NCT04008992
    Conditions
    Healthy Participants
    Interventions
    BMS-986259; Placebo; P-Aminohippurate; Iohexol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-18
    Completion
    2021-01-04
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionBMS-986259; Placebo; P-Aminohippurate; Iohexol
    PhasePhase 1
    Registry statusCompleted